Toggle Main Menu Toggle Search

Open Access padlockePrints

Browsing publications by Professor Helen Reeves.

Newcastle AuthorsTitleYearFull text
Professor Helen Reeves
Misti McCain
Discriminatory Changes in Circulating Metabolites as a Predictor of Hepatocellular Cancer in Patients with Metabolic (Dysfunction) Associated Fatty Liver Disease2023
Dr Kate Hallsworth
Dr Sam Orange
Misti McCain
Professor Helen Reeves
Feasibility of a home-based, virtually-delivered, group exercise intervention in older patients with liver cancer (TELEX-Liver Cancer)2023
Chalermsin Permtermsin
- Lalchungnunga
Dr Sirintra Nakjang
John Casement
Dr Laura Ogle
et al.
Identification of TIAM1 as a Potential Synthetic-Lethal-like Gene in a Defined Subset of Hepatocellular Carcinoma2023
Bassier Zadran
Daniel Wainwright
Dr Yvonne Bury
Dr Saimir Luli
Rachel Howarth
et al.
Impact of retrotransposon protein L1 ORF1p expression on oncogenic pathways in hepatocellular carcinoma: the role of cytoplasmic PIN1 upregulation2023
Dr Brian Ford
Dr Shruti Chachra
Katrina Rodgers
Tabassum Moonira
Dr Ziad Al-Oanzi
et al.
The GCKR-P446L gene variant predisposes to raised blood cholesterol and lower blood glucose in the P446L mouse-a model for GCKR rs12603262023
Professor Helen Reeves
John Hammond
The hepatocellular carcinoma Early Recurrence Score (ERS)—Ready for clinical implementation?2023
Dr Daniel Geh
Robyn Watson
Gourab Sen
Jeremy French
John Hammond
et al.
COVID-19 and liver cancer: Lost patients and larger tumours2022
Dr Jack Leslie
Dr Jill Hunter
Amy Collins
Amelia Rushton
Lauren Russell
et al.
c-Rel–dependent Chk2 signaling regulates the DNA damage response limiting hepatocarcinogenesis2022
Dr Jack Leslie
Erik Ramon Gil
Kathryn Gilroy
Dr Saimir Luli
Maja Laszczewska
et al.
CXCR2 inhibition enables NASH-HCC immunotherapy2022
Professor Helen Reeves
Dr Steven Masson
Genetic and pharmacological inhibition of XBP1 protects against APAP hepatotoxicity through the activation of autophagy2022
Dr Daniel Geh
Dr Jack Leslie
Professor Helen Reeves
Professor Derek Mann
Neutrophils as potential therapeutic targets in hepatocellular carcinoma2022
Professor Helen Reeves
Robyn Watson
Outcome of liver cancer patients with SARS-CoV-2 infection: An International, Multicentre, Cohort Study2022
Dr Luca Miele
Professor Helen Reeves
Rare ATG7 genetic variants predispose patients to severe fatty liver disease2022
Dr Steven Masson
Misti McCain
Professor Helen Reeves
Restoring cellular magnesium balance through Cyclin M4 protects against acetaminophen-induced liver damage2022
Professor Helen Reeves
Professor Derek Manas
Dr Peter Littler
Selective internal radiation therapy (SIRT) for hepatocellular carcinoma (HCC): Informing clinical practice for multidisciplinary teams in England2022
Dr Marco Zaki
Dr Sari Alhasan
Dr Ruchi Shukla
Misti McCain
Maja Laszczewska
et al.
Sulfatase-2 from Cancer Associated Fibroblasts: An Environmental Target for Hepatocellular Carcinoma?2022
Dr Sam Orange
Dr Kate Hallsworth
Dr Morven Brown
Professor Helen Reeves
The feasibility and acceptability of a home-based, virtual exercise intervention for older patients with hepatocellular carcinoma: protocol for a non-randomised feasibility study (TELEX-Liver Cancer)2022
Nardeen Eldafashi
Dr Rebecca Darlay
Dr Ruchi Shukla
Misti McCain
Robyn Watson
et al.
A pdcd1 role in the genetic predisposition to nafld-hcc?2021
Misti McCain
Professor Helen Reeves
Anti-miR-518d-5p overcomes liver tumor cell death resistance through mitochondrial activity2021
Professor Helen Reeves
Assessing the impact of COVID-19 on liver cancer management (CERO-19)2021
Misti McCain
Professor Derek Mann
Professor Helen Reeves
Cell-free DNA TAPS provides multimodal information for early cancer detection2021
Professor Helen Reeves
Professor Arun Sanyal
Corrigendum to ‘Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis’ [J Hepatol 75 (2021) 865–878]2021
Dr Praveen Dhondurao Sudhindar
Daniel Wainwright
Dr Santu Saha
Rachel Howarth
Misti McCain
et al.
HCV Activates Somatic L1 Retrotransposition—A Potential Hepatocarcinogenesis Pathway2021
Marco Zaki
Dr Ahmed Mahdi
Dr Gillian Patman
Anna Whitehead
Joao Mauricio
et al.
Key features of the environment promoting liver cancer in the absence of cirrhosis2021
Dr Jack Leslie
Dr Marie-Helene Ruchaud
Amy Collins
Leena Habiballa
Dr Gabi Saretzki
et al.
Neutrophils induce paracrine telomere dysfunction and senescence in ROS-dependent manner2021
Dr Luca Miele
Professor Quentin Anstee
Professor Helen Reeves
Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores2021
Professor Helen Reeves
Professor Derek Manas
Steven White
Treatment strategies for early stage hepatocellular carcinoma: a systematic review and network meta-analysis of randomised clinical trials2021
Professor Helen Reeves
Characterisation of the Serum Metabolic Signature of Cholangiocarcinoma in a United Kingdom Cohort2020
Dr Ruchi Shukla
Professor Helen Reeves
Professor Stuart McPherson
Misti McCain
Dr Praveen Dhondurao Sudhindar
et al.
Hepatitis C virus infection, endogenous retrotransposons activation and cancer risk2020
Sebastian Mafeld
Professor Helen Reeves
Professor Derek Manas
Dr Peter Littler
Early Experience of Trans-arterial Chemo-Embolisation for Hepatocellular Carcinoma with a Novel Radiopaque Bead2019
Professor Quentin Anstee
Professor Helen Reeves
Dr Olivier Govaere
From NASH to HCC: current concepts and future challenges2019
Misti McCain
Dr Luca Miele
Professor Helen Reeves
Rare Pathogenic Variants Predispose to Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease2019
Dr Catherine Willoughby
Huw Thomas
Dr Elaine Willmore
Suzanne Kyle
Dr Anita Wittner
et al.
Selective DNA-PKcs Inhibition Extends the Therapeutic Index of Localized Radiotherapy and Chemotherapy2019
Professor Alastair Burt
Professor Pierre Bedossa
Professor Helen Reeves
Data set for the reporting of intrahepatic cholangiocarcinoma, perihilar cholangiocarcinoma and hepatocellular carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR)2018
Dr Dina Tiniakos
Joao Pais Maurício-Muir
Professor Helen Reeves
Fatty liver disease and hepatocellular carcinoma: The pathologist’s view2018
Professor Jelena Mann
Professor Helen Reeves
Liquid biopsy for liver diseases2018
Dr Jane Margetts
Laura Ogle
Dr Anthony Chan
Dr David Jamieson
Dr Catherine Willoughby
et al.
Neutrophils: driving progression and poor prognosis in hepatocellular carcinoma?2018
Dr Richard McNally
Professor Helen Reeves
Reply to ‘Comment on ‘Circulating Neutrophils in patients with hepatocellular carcinoma”2018
Misti McCain
Professor Helen Reeves
The biomarker potential of Ki67 and pH2AX immunohistochemistry in guiding use of the liver-targeting nucleotide MIV-818 in patients with hepatocellular carcinoma2018
Professor Derek Manas
Professor Helen Reeves
Comparing clinical presentations, treatments and outcomes of hepatocellular carcinoma due to hepatitis C and non-alcoholic fatty liver disease2017
Misti McCain
Dr Luca Miele
Dr Paula Iruzubieta
Professor Helen Reeves
Professor Quentin Anstee
et al.
MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals2017
Dr Ziad Al-Oanzi
Sofia Fountana
Tabassum Moonira
Dr Susan Tudhope
John Petrie
et al.
Opposite effects of a glucokinase activator and metformin on glucose-regulated gene expression in hepatocytes2017
Dr Lucy Walker
Professor Ann Daly
Dr Luca Miele
Professor Quentin Anstee
Professor Helen Reeves
et al.
Telomerase reverse transcriptase germline mutations and hepatocellular carcinoma in patients with nonalcoholic fatty liver disease2017
Dr Paula Iruzubieta
Dr Steven Masson
Misti McCain
Professor Helen Reeves
The mitochondrial negative regulator MCJ is a therapeutic target for acetaminophen-induced liver injury2017
Professor Helen Reeves
Assessment of the Hong Kong Liver Cancer Staging System in Europe2016
Dr Catherine Willoughby
Professor Helen Reeves
Combination PARP and HDAC inhibition as a therapeutic strategy targeting liver cancer stem cells?2016
Tristan Reuillon
Dr Sari Alhasan
Dr Gary Beale
Annalisa Bertoli
Alfie Brennan
et al.
Design and synthesis of biphenyl and biphenyl ether inhibitors of sulfatases2016
Professor Helen Reeves
EASL Clinical Practice Guidelines on the management of benign liver tumours2016
Professor Helen Reeves
Marco Zaki
Professor Chris Day
Hepatocellular Carcinoma in Obesity, Type 2 Diabetes, and NAFLD2016
Barry Dent
Laura Ogle
Dr Rachel O'Donnell
Dr Ujjal Mallick
Professor Nicola Curtin
et al.
High-resolution imaging for the detection and characterisation of circulating tumour cells from patients with oesophageal, hepatocellular, thyroid and ovarian cancers2016
Laura Ogle
Dr James Orr
Dr Catherine Willoughby
Dr Claire Hutton
Professor Stuart McPherson
et al.
Imagestream detection and characterisation of circulating tumour cells - a liquid biopsy for hepatocellular carcinoma?2016
Dr Mat Elameer
Jeremy French
Professor Derek Manas
Professor Helen Reeves
Dr Peter Littler
et al.
Implementation of a one-stop multidisciplinary clinic for liver-directed therapy in patients with primary or secondary liver malignancies2016
Professor Helen Reeves
Professor Derek Manas
Long-term impact of liver function on curative therapy for hepatocellular carcinoma: application of the ALBI grade2016
Professor Helen Reeves
Role of the GALAD and BALAD-2 Serologic Models in Diagnosis of Hepatocellular Carcinoma and Prediction of Survival in Patients2016
Dr Sari Alhasan
Dr Beate Haugk
Laura Ogle
Dr Gary Beale
Anna Long
et al.
Sulfatase-2: a prognostic biomarker and candidate therapeutic target in patients with pancreatic ductal adenocarcinoma2016
Marco Zaki
Professor Helen Reeves
The genetic heterogeneity of hepatocellular carcinoma and the implications for personalised medicine2016
Dr Sheba Macheka
Dr David Jamieson
Professor Helen Reeves
Misti McCain
The isolation and characterisation of circulating tumour cells from patients with hepatocellular carcinoma2016
Professor Helen Reeves
Urinary Metabotyping of Hepatocellular Carcinoma in a UK Cohort Using Proton Nuclear Magnetic Resonance Spectroscopy2016
Dr Richard Speight
Anna Whitehead
Dr Gillian Patman
Dr John Mansfield
Professor Helen Reeves
et al.
Activation of the bile acid receptor, Farnesoid-X Receptor, may reduce Ileal Inflammatory Cytokine expression in an animal model of diet-induced obesity2015
Professor Helen Reeves
Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach - The ALBI Grade2015
Professor Helen Reeves
Assessment of the Hong Kong Liver Cancer Staging System in Europe2015
Liam Cornell
Dr Joanne Martin
Laura Ogle
Dr Catherine Willoughby
Dr Despina Televantou
et al.
DNA-PK-A Candidate Driver of Hepatocarcinogenesis and Tissue Biomarker That Predicts Response to Treatment and Survival2015
Anna Whitehead
Dr Gillian Patman
Professor Chris Day
Dr Dina Tiniakos
Professor Quentin Anstee
et al.
Effects of FXR agonist PX20606 on tumour formation in animal models of non-alcoholic fatty liver disease2015
Professor Helen Reeves
Hepatocellular Carcinoma: Optimal Staging Impacts Survival2015
Anna Whitehead
Laura Ogle
Dr Gillian Patman
Dr Ali Anwar
Dr Dina Tiniakos
et al.
Ras and p-ERK in metabolic syndrome associated Hepatocellular Carcinoma (HCC)2015
Duncan Miller
Dr Benoit Carbain
Dr Gary Beale
Dr Sari Alhasan
Professor Helen Reeves
et al.
Regioselective sulfamoylation at low temperature enables concise syntheses of putative small molecule inhibitors of sulfatases2015
Dr Cedric Simillion
Professor Helen Reeves
Regular exercise decreases liver tumors development in hepatocyte-specific PTEN-deficient mice independently of steatosis2015
Professor Quentin Anstee
Dr Yang-Lin Liu
Professor Chris Day
Professor Helen Reeves
Reply to: HCC and liver disease risk in homozygous PNPLA3 p.I148M carriers approach monogenic inheritance2015
Professor Helen Reeves
Dr Luca Miele
Professor Quentin Anstee
Telomerase reverse transcriptase mutations are associated with hepatocellular carcinoma in nash2015
Professor Helen Reeves
The 'Galad Score' for serological Detection of Hepatocellular Cercinoma: International Validation and Assesment of the Influence of Tumor size and Aetiology on Model Utility2015
Professor Helen Reeves
A positive feedback loop between RIP3 and JNK controls non-alcoholic steatohepatitis2014
Dr Yang-Lin Liu
Dr Gillian Patman
Julian Leathart
Professor Alastair Burt
Professor Chris Day
et al.
Carriage of the PNPLA3 rs738409 C>G Polymorphism Confers an Increased Risk of Non-Alcoholic Fatty Liver Disease Associated Hepatocellular Carcinoma2014
Barry Dent
Dr Rachel O'Donnell
Laura Ogle
Padmini Ramesh
Nick Hayes
et al.
Detection and characterization of circulating tumor cells by imaging flow cytometry2014
Dr Laura Ogle
Dr David Jamieson
Dr Rachel O'Donnell
Barry Dent
Professor Nicola Curtin
et al.
Detection of circulating tumour cells (CTCS) in hepatocellular (HCC) cancer patients using the ImageStreamx2014
Dr Jess Dyson
Dr Dipanker Chattopadhyay
Rajiv Lochan Jayadeva
Dr Imran Patanwala
Mike Cole
et al.
Hepatocellular cancer: The impact of obesity, type 2 diabetes and a multidisciplinary team2014
Professor Quentin Anstee
Dr Mark Hudson
Professor Helen Reeves
Reply to "Hepatocellular carcinoma and the Newcastle-upon-Tyne area"2014
Dr Gillian Patman
Professor Helen Reeves
The Detection of Hepatocellular Carcinoma Using a Prospectively Developed and Validated Model Based on Serological Biomarkers2014
Dr Yang-Lin Liu
Professor Helen Reeves
Professor Alastair Burt
Dr Dina Tiniakos
Professor Stuart McPherson
et al.
TM6SF2 rs58542926 Influences Hepatic Fibrosis Progression in Patients with Non-Alcoholic Fatty Liver Disease2014
Anna Whitehead
Dr Gillian Patman
Liam Cornell
Dr Despina Televantou
Professor Nicola Curtin
et al.
A Role for DNA Repair Protein Kinase (DNA-PK) in the Progression of Simple Steatosis to Steatohepatitis (NASH)?2013
Dr Yang-Lin LIU
Dr Gillian Patman
Julian Leathart
Professor Alastair Burt
Professor Chris Day
et al.
Carriage of PNPLA3 I148M is Associated with an Increased Risk of Non-Alcoholic Fatty Liver Disease Associated Hepatocellular Carcinoma2013
Professor Helen Reeves
Effect of Regular Training on Hepatocellular Carcinoma Development in Hepatocyte-Specific Pten-Deficient Mice2013
Professor Chris Day
Professor Mark Walker
Professor Helen Reeves
Krüppel Like Factor 6 (KLF6) Protects From NAFLD Progression through Regulation of Adipose Tissue Insulin Resistance2013
Dr Gillian Patman
Dr Despina Televantou
Anna Whitehead
Professor Chris Day
Professor Fiona Oakley
et al.
Mild Steatosis and Impaired Glucose Tolerance are Associated with Liver Cancer Development, While Progression to Nash Increases Number/Size in an Animal Model of NAFLD2013
Dr Gillian Patman
Professor Loranne Agius
Douglas Hui
Dr Despoina Televantou
Professor Helen Reeves
et al.
Post-transcriptional activation of PPAR alpha by KLF6 in hepatic steatosis2013
Dr Gillian Patman
Dr Despina Televantou
Anna Whitehead
Professor Chris Day
Professor Alastair Burt
et al.
Sulfatase-2 (SULF2) Expressed in Hepatocytes and Stromal Cells Contributes to the Development of Steatosis, the Progression of NAFLD to Fibrosis and the Advancement of Cancer2013
John Petrie
Dr Gillian Patman
Ishita Sinha
Professor Helen Reeves
Professor Loranne Agius
et al.
The rate of production of uric acid by hepatocytes is a sensitive index of compromised cell ATP homeostasis2013
Liam Cornell
Dr Joanne Martin
Professor Nicola Curtin
Professor Helen Reeves
DNA-PK or ATM inhibition inhibits non-homologous end joining and enhances chemo- and radio sensitivity in hepatocellular cancer cell lines2012
Professor Quentin Anstee
Dr Rebecca Darlay
Julian Leathart
Professor Helen Reeves
Professor Alastair Burt
et al.
Genome-Wide Association Analysis Confirms Importance of PNPLA3 and Identifies Novel Variants Associated With Histologically Progressive Steatohepatitis in NAFLD2012
Dr Gillian Patman
Laura Pascoe
Dr Luca Miele
Douglas Hui
Professor Alastair Burt
et al.
Glucokinase links Krüppel-like factor 6 to the regulation of hepatic insulin sensitivity in nonalcoholic fatty liver disease2012
Douglas Hui
Stuart Robinson
Dr Gillian Patman
Professor Derek Manas
Professor Helen Reeves
et al.
KLF6 splice variant 1 in patients with colorectal liver metastasis correlates with a higher clinical risk score2012
Dr Gillian Patman
Douglas Hui
Professor Quentin Anstee
Professor Helen Reeves
Kruppel-like factor 6 splice variant 3 (KLF6-SV3) - The redox sensitive splice variant of KLF6 expressed in non-alcoholic steatohepatitis (NASH)2012
Dr Despoina Televantou
Douglas Hui
Rajiv Lochan Jayadeva
Richard Charnley
Professor Alastair Burt
et al.
Membranous expression of sulfatase-2 is associated with a poorer prognosis in patients following pancreatic cancer resection2012
Dr Gillian Patman
Douglas Hui
Professor Quentin Anstee
Professor Helen Reeves
Oxidative stress induces alternative splicing and nuclear translocation of kruppel like factor 62012
Dr Sari Alhasan
Dr Gary Beale
Professor Herbie Newell
Professor Helen Reeves
Suppression of SULF2, an extracellular endosulfatase up-regulated in hepatocellular cancers, modulates WNT signalling and inhibits cell growth2012
Professor Helen Reeves
Professor Loranne Agius
The Kruppel-like factor 6-IVS1-27A (KLF6) polymorphism is associated with more favourable postprandial glucose metabolism in subjects at high risk of type 2 diabetes2012
Rajiv Lochan Jayadeva
Professor Ann Daly
Professor Helen Reeves
Richard Charnley
Family history of cancer and tobacco exposure in index cases of pancreatic ductal adenocarcinoma2011
Dr Gillian Patman
Professor Quentin Anstee
Professor Helen Reeves
Hepatocellular Carcinoma in NASH: Is there a biological Rationale?2011
Dr Imran Patanwala
Professor Derek Manas
Dr Mark Hudson
Professor Helen Reeves
NAFLD and the changing face of hepatocellular cancerER (HCC)2011
Dr Imran Patanwala
Dr John Rose
Bryon Jaques
Professor Derek Manas
Dr Mark Hudson
et al.
NAFLD related HCC is rising dramatically in the North of England2011
Rajiv Lochan Jayadeva
Professor Ann Daly
Professor Helen Reeves
Richard Charnley
The role of tobacco derived carcinogens in pancreas cancer2011
Laura Pascoe
Dr Luca Miele
Professor Helen Reeves
Kruppel like factor 6 (KLF6) regulates heaptic insulin resistance (HEP-IR)2010
Dr Gillian Patman
Professor Loranne Agius
Professor Helen Reeves
Liver-specific deletion of KLF6 uncovers novel transcriptional pathways linked to lipid and glucose homeostasis2010
Liam Cornell
Dr Joanne Martin
Febrina Budhisetiawan
Professor Herbie Newell
Professor Derek Manas
et al.
Synthetic lethality in liver cancer cell lines treated with inhibitors of DNA double strand break repair2010
Dr Joseph Gray
Dr Dipanker Chattopadhyay
Dr Gary Beale
Dr Gillian Patman
Dr Luca Miele
et al.
A proteomic strategy to identify novel serum biomarkers for liver cirrhosis and hepatocellular cancer in individuals with fatty liver disease2009
Dr Gary Beale
Ahmad Alserri
Dr Luca Miele
Dr Gillian Patman
Professor Ann Daly
et al.
Claudin 10 (CLDN10) - a Candidate Suceptibility Gene for NAFLD Progression2009
Dr Gillian Patman
Professor Helen Reeves
Kruppel-like factor 6 in chronic liver disease and hepatocellular cancer2009
Dr Gary Beale
Laura Pascoe
Dr Luca Miele
Professor Mark Walker
Professor Chris Day
et al.
The Kruppel-Like Factor 6 (KLF6) Genotype Which is Associated With NAFLD Progression is Associated with Higher Fasting Serum Glucose Levels in Healthy Individuals2009
Dr Gary Beale
Dr Dipanker Chattopadhyay
Dr Joseph Gray
Dr Stephen Stewart
Dr Mark Hudson
et al.
AFP, PIVKAII, GP3, SCCA-1 and follisatin as surveillance biomarkers for hepatocellular cancer in non-alcoholic and alcoholic fatty liver disease2008
Rajiv Lochan Jayadeva
Professor Ann Daly
Professor Helen Reeves
Richard Charnley
Genetic susceptibility in pancreatic ductal adenocarcinoma2008
Dr Luca Miele
Dr Gary Beale
Dr Gillian Patman
Julian Leathart
Professor Chris Day
et al.
The Kruppel-like factor 6 genotype is associated with fibrosis in nonalcoholic fatty liver disease2008
Dr Nicholas Thompson
Professor Alastair Burt
Professor Chris Day
Professor Helen Reeves
Warfarin induced cholestatic jaundice in a patient receiving total parenteral nutrition2008
Dr Gary Beale
Dr Luca Miele
Professor Helen Reeves
Professor Chris Day
Differential expression of GSTT1 and GSTT2 is associated with more advanced fibrosis in patients with NAFLD2007
Dr Dipanker Chattopadhyay
Professor Helen Reeves
Oncogenes and tumour suppressor genes2007
Dr Dipanker Chattopadhyay
Professor Derek Manas
Professor Helen Reeves
The development of targeted therapies for hepatocellular cancer2007
Dr Luca Miele
Dr Gary Beale
Julian Leathart
Professor Chris Day
Professor Helen Reeves
et al.
The KLF6 (IVS1-27G > a) polymorphism is associated with non-progressive NAFLD2007
Professor Chris Day
Professor Helen Reeves
The genetic basis of hepatocellular cancer2006
Professor Helen Reeves
A germline DNA polymorphism enhances alternative splicing of the KLF6 tumor suppressor gene and Is associated with increased prostate cancer risk2005
Professor Helen Reeves
Absence of KLF6 gene mutation in 71 hepatocellular carcinomas: Reply2005
Professor Helen Reeves
Management of hepatocellular cancer2005
Professor Helen Reeves
Targeted inhibition of the KLF6 splice variant, KLF6 SV1, suppresses prostate cancer cell growth and spread2005
Dr Barry King
Dr Pamela MacDonald
Dr Dipanker Chattopadhyay
Professor Helen Reeves
The Kruppel-like factor 6 tumour suppressor induces apoptosis in HepG2 cells2005
Professor Helen Reeves
Cyclin-dependent kinase inhibition by the KLF6 tumor suppressor protein through interaction with cyclin D12004
Professor Helen Reeves
Frequent inactivation of the tumor suppressor Kruppel-like factor 6 (KLF6) in hepatocellular carcinoma2004
Professor Helen Reeves
Kruppel-like factor 6 (KLF6) is a tumor-suppressor gene frequently inactivated in colorectal cancer2004
Professor Helen Reeves
Novel growth suppressor targets of the KLF6 tumor suppressor gene identified by stringent microarray analysis2003
Professor Helen Reeves
Activation of hepatic stellate cells: a key issue in liver fibrosis2002
Professor Helen Reeves
KLF6, a candidate tumor suppressor gene mutated in prostate cancer2001
Professor Helen Reeves
Professor Alastair Burt
Professor Chris Day
Integrin receptor expression changes in diseased hepatic stellate cells2001
Professor Helen Reeves
Professor Derek Manas
Professor Margaret Bassendine
Dr Mark Hudson
Emeritus Professor Oliver James
et al.
Intravenous bisphosphonate pre liver transplant prevents osteoporotic vertebral collapse1996
Professor Helen Reeves
Professor Alastair Burt
Emeritus Professor Oliver James
Lipocyte activation occurs in the absence of hepatitis in alcoholic liver disease and correlates with the severity of steatosis1994